Back to Results
First PageMeta Content
Growth hormones / Medicine / Growth factors / Endocrinology / Insulin-like growth factor 1 / Tercica / Insulin-like growth factor / Mecasermin / Growth hormone treatment / Biology / Peptide hormones / Endocrine system


PRIOR AUTHORIZATION POLICY Increlex® (mecasermin [rDNA origin] injection Tercica) TO INITIATE A COVERAGE REVIEW, CALL[removed]
Add to Reading List

Document Date: 2013-10-03 14:59:14

Open Document

File Size: 121,09 KB

Share Result on Facebook

City

Savage / Rosenbloom / Chernausek / Brisbane / Ranke / /

Company

Tercica Inc / Primary IGFD / Hospira Incorporated / /

Country

United States / /

Facility

National Library of Medicine / /

IndustryTerm

treatment of growth failure / treatment of growth hormone insensitivity disorders / /

MedicalCondition

malnutrition / hypothyroidism / chronic treatment / nutritional deficiencies / Thyroid deficiencies / deficiency / GH deficiency / disorders / /

Organization

Food and Drug Administration / /

/

Position

principal hormonal mediator / physician / /

Product

Increlex / /

ProvinceOrState

Missouri / South Dakota / Alabama / Manitoba / /

Technology

antibodies / /

URL

http /

SocialTag